Dynamix Pharmaceuticals Completes a $10M Series A Financing
Signs a Collaboration Deal with Teva Pharmaceutical Industries
Dynamix Pharmaceuticals announced that they have closed a $10 million financing round. The financing was led by Batsheva Elran, Founder and Managing Partner of Opal Ventures, as a Medica3 fund investment with Teva Pharmaceutical Industries Ltd.
Dynamix Pharmaceuticals, founded by Dr. Oren M. Becker, who serves as its President and CEO, also announced that it has signed a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. for the discovery and development of up to two of Dynamix drug candidates.
Under the terms of the agreement, Dynamix will be eligible to earn milestones based on the achievement of certain discovery, development, regulatory and commercial milestones. Dynamix will also receive tiered royalties on sales by Teva of the collaboration-developed product sales.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

glyconet Berlin Brandenburg e.V. - Potsdam, Germany
Medicom,_the_African_Journal_of_Hospital_Medicine
Highlights of June 2017 EMA Management Board meeting - Focus on Brexit preparations and the development of the EU clinical trial portal and database

Promising new therapy to target MAGE-A1 positive solid tumors - T-knife Therapeutics announces dosing of first patient with TK-8001 in the IMAG1NE phase 1/2 clinical trial
Bitop AG Reports That Ectoin Reduces Symptoms of Acute Allergic Rhinitis
